Poly-MVA Cancer Trials Yield Impressive Results

    The inventor, Dr. Merrill Garnett, spent nearly 40 years probing the realm of “electrogenetics”, in an effort to create a substance that could “interrupt and offset the energy flow in cancer cells and produce their selective destruction”. His view of cancer is that it is a failure of cells to regenerate normally due to a problem in the cell’s metabolic processes. Dr. Garnett set off to develop a molecular compound that could restore missing pathways and healthy energetic behavior to cancer cells. After experimenting with 20,000 different compounds, he created a molecule containing palladium, lipoic acid, B-12, and thiamine.

    This substance, named Poly-MVA, first demonstrated itself to be effective against cancer in animal studies and on many different cancer cell lines. Animal toxicology studies and safety studies have showed the substance to be safe, even when given at very high levels. Mice were given 5000mg/kg of Poly-MVA in an effort to discover a lethal level of the substance, but no death or signs of organ damage were found. The typical human dose is only 20mg/kg. Two human safety studies yielded no severe adverse events, but only ordinary adverse events such as headache, fatigue, etc.

    Dr. James Forsythe has conducted some informal clinical trials involving Poly-MVA on cancer:

    Poly-MVA Standalone Trials

    One investigation tested Poly-MVA as a standalone therapy. The data for 212 stage IV cancer patients was presented at 26 months and at 30 months. The patients were divided into two groups. One group received Poly-MVA plus a low dose chemotherapy regimen. The other group received only Poly-MVA. In both groups, the Poly-MVA was given by IV for the first 15 days, then switched to oral. A “response” was defined as a stabilization, partial remission, or complete remission of cancer.

    At 26 months, the chemo and Poly-MVA group had a 61% response. The Poly-MVA only group had a 51% response. A subgroup which took Poly-MVA orally but did not have the intial IV loading had 39% response.

    By 30 months, 39 patients had discontinuted the therapy in less than 3 months, leaving 212-39 = 173 patients. 98 of those remaining patients had expired. Some of those that expired did so after discontinuing the therapy, but let us assume pessimistic performance and assume that had they continued therapy, all of those patients still would have expired anyway. That means that By 30 months, (173-98)/173*100% = 43% of relevant patients were still alive.

    By 4 years, Dr. Forsythe reported a survival-rate of 32%.

    Note the this survival rate is for stage IV patients. Actually, not only that, but it is for stage IV patients that already have weakened systems due to failed chemotherapy. Had they wanted Poly-MVA from the start, these patients would not all be stage IV. Integrative physicians typically don’t get their hands on cancer patients until they are left for dead for the mainstream.

    Remembering that, make a qualitative comparison between a 4-year-survival-rate of 32% of stage IV chemo-resistant patients with a protocol involving Poly-MVA versus historical statistics on life expectancy of chemo resistant stage IV patients for various cancers. As usual, I cannot find the desired cancer statistics easily on the web (it seems to me they make it hard to find cancer stats on purpose…), so I have to trust the numbers that Dr. Forsythe has presented as historical controls for stage IV chemo-resistant cancer life expectencies:

      STAGE IV HISTORICAL
      CONTROLS (Chemo-resistant)

      Breast 6 – 12 months
      Colorectal 3 – 6 months
      Head / Neck 4 – 8 months
      Hematological 6 – 8 months
      Lung 3 – 6 months
      Prostate 6 – 9 months

    So qualitatively, Poly-MVA greatly improved outcomes over a very grim historical picture.

    Not only that, but side effects were basically negligible. Less than 5% had diarrhea, less than 5% had shortness of breath, and less than 5% had transfusion reactions.

    Poly-MVA Trials Along with Other Therapies

    A later investigation by Dr. Forsythe reported at 33 months on 250 stage IV patients that were divided into groups involving various combinations of chemo, a homeopathic called “salicinium” (that has some molecular similarities to laetrile), and Poly-MVA. These trials actually highlight the effectiveness of salicinium (Orasal), so I do not want to digress here. But in short, across all groups, the results showed absolutely crushing superiority when compared to historical expected lifespans for various stage IV cancers. The 33 month survival rate across all groups was 70%. (Update…read the first few comments below, discussing whether or not this is really a homeopathic medicine or not)

    In addition to the results reported by Dr. Forsythe, anecdotal successes can be found all over the web.

    The Takeaway Message

    The evidence presented by Dr. Forsythe demonstrates that Poly-MVA works to some unclear degree. And if these kind of results were recieved in stage IV patients that were aleady weakened by chemotherapy, one can imagine the results would be excellent if treatment were initiated during stage I or II and in lieu of any chemotherapy. Now compare those potential results to those of chemotherapy which is statistically shown to basically not work at all!

    Hmmm…if I were forced to pick between only Poly-MVA and chemotherapy, what would I choose? Would I choose something that works to some extent and has little side effects? Or would I choose something that works to NO extent and has TONS of side effects?

    Poly-MVA is not just a supplement with the individual labeled ingredients. These ingredients are molecularly arranged in a special way to give it special properties. Poly-MVA is completely soluble in both water and fat, making it easily move throughout the body, crossing the blood-brain barrier, and entering every cell. This makes Poly-MVA especially appealing in cases of brain tumors or other instances where desired drugs or remedies simply cannot travel to where they are needed.

    Some claimed therapeutic benefits include destroying cancer cells by stealing their electromagnetic energy (reduction), invigorating normal cells, repairing damage left by cancer, shrinking tumors, inducing apoptosis due to inhibition of cancer energy metabolism, preventing new cancer cell plasma membrane synthesis, promoting normal cell proliferation around dead cancer cells, stimulating leukocytes to remove cancer debris, and reducing the incidence of cachexia.

    It is said that Poly-MVA repairs abnormally altered genes necessary to set cancer mechanisms into action, though the inventor of Poly-MVA admits that all the mechanisms of action at the cellular level are not known.

    It is believed that taking excessive doses of antioxidants while on Poly-MVA might reduce its benefits. Aside from this contraindication – which I would debate-, it appears that Poly-MVA can be used synergistically with other cancer treatments. A serious four-month course of Poly-MVA costs about $3,600, plus the cost of working with a supportive doctor.

    Poly-MVA is currently used by at least 100 doctors in the USA who officially list themselves as utilizing this therapy. Dr. Garnett is planning to continue gathering required information to get FDA approval to start FDA trials. Poly-MVA is also being successfully used in a number of other countries.

    In light of the significant evidence of both safety and effectiveness, Poly-MVA makes itself a reasonable alternative treatment option that can be used synergistically with other alternatives. For those that are interested, take a look at their layman’s poster:

    More info: 1, 2, 3, 3b, 3c, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18

    Disclaimer: This article does not contain any medical advice. This website contains opinion and is for informational purposes only. If seeking medical advice, consult a licensed physician.

      Related Articles:



      3 Responses to “Poly-MVA Cancer Trials Yield Impressive Results”

      1. Love the article – very well explained! Is there a way that I can use that poster on our site?

        If you can let me know, that would be great!

      2. You refer to Salicinium as ‘homeopathic’ but its claimed operation seems simply pharmaceutical and the treatment involves nothing of the theories underlying homeopathy, such as increasing effectiveness by diluting the homeopathic ingredient to nonexistent levels and relying on water molecules’ ‘memory’ of once having been in contact with the homeopathic ingredient. Should Salicinium’s claimed selective killing of cancer cells be proven, this would provide no support for traditional homeopathic theory or treatments.

      3. Scientific Living on October 23rd, 2011 at 5:00 pm

        Hi Hans. Thanks for that comment. I think you are totally correct, and I have actually been meaning to edit this article, and will probably do so momentarily. Yes, this does not seem to be a homeopathic treatment. If you look at the product label, there are more than just homeopathic ingredients. I am sad there is so little information on this treatment in the public domain, and someday I will write an article on this topic when I know more. There was a doctor who had a lengthy explanation of how it works on his site (and it was pharmacological), but he was asked to take it down by people who had some kind of legal rights to the treatment. So there may be some desire for money or prestige in that some doctors want to be the ones to break the news to the world. Also, I suspect that if there is in fact some official classification of it as a homeopathic medicine that it perhaps was done intentionally to fly under the radar of the FDA, which likes to classify things such as cherries as unapproved drugs (no joke). Also, it should be noted that Salicinium is also called glycobenzaldehyde. Laetrile is a cancer therapy with some amount of research behind it, and it has benzaldehyde in its chemical formula. Also, benzaldehyde itself has some research behind it for cancer. So there are a lot of questions to be asked about this treatment, that at present, perhaps only those in the “in crowd“ could answer correctly.

        Thanks,
        David

      Leave a Reply